Stockscreener 앱 받기
2.29
10.63%
0.22
시간 외 거래:
2.27
-0.02
-0.87%
전일 마감가:
$2.07
열려 있는:
$2.1
하루 거래량:
3.61M
Relative Volume:
2.21
시가총액:
$260.82M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-1.0553
EPS:
-2.17
순현금흐름:
$-132.53M
1주 성능:
+13.37%
1개월 성능:
-28.21%
6개월 성능:
-37.26%
1년 성능:
-4.18%
1일 변동 폭
$2.07
$2.36
1주일 범위
$2.01
$3.50
52주 변동 폭
$1.96
$8.83
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| FATE | 2.29 | 260.82M | 13.45M | -178.23M | -132.53M | -2.17 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-07-28 | 개시 | Needham | Hold |
| 2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
| 2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Jefferies | Buy |
| 2021-02-26 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-27 | 재개 | H.C. Wainwright | Neutral |
| 2020-05-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 재확인 | Mizuho | Buy |
| 2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-06-07 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 개시 | Jefferies | Buy |
| 2018-08-01 | 개시 | Citigroup | Buy |
| 2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - Defense World
Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook - Investing.com
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN
Needham & Company LLC Reaffirms Hold Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Thera rockets on early data for FT819 - The Pharma Letter
Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com
BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Fate Therapeutics Presents 6-Month Follow-up Data on First - GlobeNewswire
Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - Yahoo Finance
Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Fate Therapeutics stock hits 52-week low at $2.09 By Investing.com - Investing.com Canada
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges - TipRanks
Fate Therapeutics Unveils Q3 2024 Financial Highlights - TipRanks
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus - Yahoo Finance
BMO cuts Fate Therapeutics stock target, keeps market rating on initial data - Investing.com UK
Fate Therapeutics: Q3 Earnings Snapshot - CT Insider
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com UK
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - The Manila Times
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - The Manila Times
Fate Therapeutics Highlights Cancer-selective, - GlobeNewswire
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - GlobeNewswire Inc.
Fate Therapeutics Presents Pan-tumor Targeting Preclinical - GlobeNewswire
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Inc (FATE) Worth Considering For The Next Few Weeks - Stocks Register
Karyopharm Therapeutics Inc (KPTI) Is Worth Accumulating At Current Levels - Stocks Register
Global T-cell Therapy Market Trend [2024-2032] | Consumer Demographics - WICZ
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat
Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News
Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News
Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat
Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily
Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):